{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:52:13Z","timestamp":1784332333366,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-156306"],"award-info":[{"award-number":["PJT-156306"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SHI-155404"],"award-info":[{"award-number":["SHI-155404"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>With the ongoing opioid crisis and policy changes regarding legalization of cannabis occurring around the world, it is necessary to consider cannabis use in the context of opioid use disorder (OUD) and its\u00a0treatment. We aimed to examine (1) past-month cannabis use in patients with OUD, (2) self-reported cannabis-related side effects and craving, and (3) the association between specific characteristics of cannabis use and opioid use during treatment in cannabis users.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants receiving pharmacological treatment for OUD (<jats:italic>n<\/jats:italic>\u2009=\u20092315) were recruited from community-based addiction treatment clinics in Ontario, Canada, and provided information on past-month cannabis use (self-report). Participants were followed for 3\u00a0months with routine urine drug screens in order to assess opioid use during treatment. We used logistic regression analysis to explore (1) the association between any cannabis use and opioid use during treatment, and (2) amongst cannabis-users, specific cannabis use characteristics associated with opioid use. Qualitative methods were used to examine responses to the question: \u201cWhat effect does marijuana have on your treatment?\u201d.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Past-month cannabis use was reported by 51% of participants (<jats:italic>n<\/jats:italic>\u2009=\u20091178). Any cannabis use compared to non-use was not associated with opioid use (OR\u2009=\u20091.03, 95% CI 0.87\u20131.23, <jats:italic>p<\/jats:italic>\u2009=\u20090.703). Amongst cannabis users, nearly 70% reported daily use, and half reported experiencing cannabis-related side effects, with the most common side\u00a0effects being slower thought process (26.2%) and lack of motivation (17.3%). For cannabis users, daily cannabis use was associated with lower odds of opioid use, when compared\u00a0  with occasional use (OR\u2009=\u20090.61, 95% CI 0.47\u20130.79, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) as was older age of onset of cannabis use (OR\u2009=\u20090.97, 95% CI 0.94, 0.99, <jats:italic>p<\/jats:italic>\u2009=\u20090.032), and reporting cannabis-related side effects (OR\u2009=\u20090.67, 95% CI 0.51, 0.85, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Altogether, 75% of cannabis users perceived no impact of cannabis on their OUD\u00a0treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Past-month cannabis use was not associated with more or less opioid use during treatment. For patients who use cannabis, we identified specific characteristics of cannabis use associated with differential outcomes. Further examination of  characteristics and patterns of cannabis use is warranted and may inform more tailored assessments and treatment recommendations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-021-00468-6","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T13:03:23Z","timestamp":1614085403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The association between cannabis use and outcome in pharmacological treatment for opioid use disorder"],"prefix":"10.1186","volume":"18","author":[{"given":"Tea","family":"Rosic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveena","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balpreet","family":"Panesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren B.","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika","family":"Sanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Worster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5974-9361","authenticated-orcid":false,"given":"Zainab","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"468_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.3254","author":"M Cerd\u00e1","year":"2019","unstructured":"Cerd\u00e1 M, Mauro C, Hamilton A, et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry. 2019. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.3254.","journal-title":"JAMA Psychiatry"},{"key":"468_CR2","unstructured":"Rocky Mountain High Intensity Drug Trafficking Area. The legalization of marijuana in Colorado: the impact. 2019. https:\/\/rmhidta.org\/default.aspx?act=documents2.aspx&DocumentCategoryID=27. Accessed 15 Jan 2020"},{"key":"468_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13293-017-0130-1","volume":"8","author":"L Zielinski","year":"2017","unstructured":"Zielinski L, Bhatt M, Sanger N, Plater C, Worster A, Varenbut M, et al. Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences. Biol Sex Differ. 2017;8:8. https:\/\/doi.org\/10.1186\/s13293-017-0130-1.","journal-title":"Biol Sex Differ"},{"key":"468_CR4","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: Apparent opioid-related deaths in Canada (January 2016 to\u00a0December\u00a02018). Web Based Report. Ottawa: Public Health Agency of Canada; June 2019."},{"key":"468_CR5","doi-asserted-by":"crossref","unstructured":"Fischer B, Kurdyak P, Goldner E et al. Treatment of prescription opioid disorders in Canada: looking at the \u2018other epidemic\u2019? Subst Abuse Treat Prev Policy. 2016;11:12.","DOI":"10.1186\/s13011-016-0055-4"},{"key":"468_CR6","doi-asserted-by":"publisher","unstructured":"Ontario Drug Policy Research Network. Ontario Prescription Opioid Tool. Toronto, ON; July 2018. https:\/\/doi.org\/10.31027\/ODPRN.2018.01. https:\/\/odprn.ca\/ontario-opioid-drug-observatory\/ontario-prescription-opioid-tool\/","DOI":"10.31027\/ODPRN.2018.01"},{"key":"468_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd002209.pub2","author":"RP Mattick","year":"2009","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Data of Sys Rev. 2009. https:\/\/doi.org\/10.1002\/14651858.cd002209.pub2.","journal-title":"Cochrane Data of Sys Rev"},{"key":"468_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd002207","author":"R Mattick","year":"2003","unstructured":"Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Data Syst Rev. 2003. https:\/\/doi.org\/10.1002\/14651858.cd002207.","journal-title":"Cochrane Data Syst Rev"},{"key":"468_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/2046-4053-3-105","volume":"3","author":"BB Dennis","year":"2014","unstructured":"Dennis BB, Naji L, Bawor M, Bonner A, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. Syst Rev. 2014;3:105.","journal-title":"Syst Rev"},{"key":"468_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF03256276","volume":"12","author":"Y Li","year":"2008","unstructured":"Li Y, Kantelip J-P, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response. Mol Diagn Ther. 2008;12:109\u201324.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"468_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2105\/AJPH.85.1.83","volume":"85","author":"DM Hartel","year":"1995","unstructured":"Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health. 1995;85(1):83\u20138.","journal-title":"Am J Public Health"},{"issue":"1","key":"468_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/09595230601036994","volume":"26","author":"M Stenbacka","year":"2007","unstructured":"Stenbacka M, Beck O, Leifman A, Romelsj\u00f6 A, Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alc Rev. 2007;26(1):55\u201363. https:\/\/doi.org\/10.1080\/09595230601036994.","journal-title":"Drug Alc Rev"},{"issue":"3","key":"468_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0376-8716(98)00092-1","volume":"52","author":"DA Wasserman","year":"1998","unstructured":"Wasserman DA, Weinstein MG, Havassy BE, Hall SM. Factors associated with lapses to heroin use during methadone maintenance. Drug Alc Depend. 1998;52(3):183\u201392. https:\/\/doi.org\/10.1016\/s0376-8716(98)00092-1.","journal-title":"Drug Alc Depend"},{"issue":"4","key":"468_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/adm.0000000000000406","volume":"12","author":"I Bagra","year":"2018","unstructured":"Bagra I, Krishnan V, Rao R, Agrawal A. Does cannabis use influence opioid outcomes and quality of life among buprenorphine maintained patients? A cross-sectional. Comparative Study J Addict Med. 2018;12(4):315\u201320. https:\/\/doi.org\/10.1097\/adm.0000000000000406.","journal-title":"Comparative Study J Addict Med"},{"issue":"4","key":"468_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1046\/j.1360-0443.1998.9344935.x","volume":"93","author":"AJ Budney","year":"1998","unstructured":"Budney AJ, Bickel WK, Amass L. Marijuana use and treatment outcome among opioid-dependent patients. Addiction. 1998;93(4):493\u2013503. https:\/\/doi.org\/10.1046\/j.1360-0443.1998.9344935.x.","journal-title":"Addiction"},{"issue":"4","key":"468_CR16","doi-asserted-by":"publisher","first-page":"E665","DOI":"10.9778\/cmajo.20190026","volume":"7","author":"H McBrien","year":"2019","unstructured":"McBrien H, Luo C, Sanger N, Zielinski L, Bhatt M, Zhu XM, Marsh DC, Thabane L, Samaan Z. Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis. CMAJ Open. 2019;7(4):E665\u201373. https:\/\/doi.org\/10.9778\/cmajo.20190026.","journal-title":"CMAJ Open"},{"issue":"1\u20132","key":"468_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.drugalcdep.2013.02.030","volume":"132","author":"KP Hill","year":"2013","unstructured":"Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, Woody GE, Weiss RD. Association of cannabis use with opioid outcomes among opioid-dependent youth. Drug Alcohol Depend. 2013;132(1\u20132):342\u20135. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.030.","journal-title":"Drug Alcohol Depend"},{"issue":"154","key":"468_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.drugalcdep.2015.05.013","volume":"1","author":"A Bisaga","year":"2015","unstructured":"Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend. 2015;1(154):38\u201345. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.05.013.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"468_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1151\/ascp07414","volume":"4","author":"AJ Budney","year":"2007","unstructured":"Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4(1):4. https:\/\/doi.org\/10.1151\/ascp07414.","journal-title":"Addict Sci Clin Pract"},{"key":"468_CR20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2147\/NDT.S129480","volume":"13","author":"T Rosic","year":"2017","unstructured":"Rosic T, Naji L, Bawor M, et al. The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study. Neuropsychiatr Dis Treat. 2017;13:1399\u2013408.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"468_CR21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.","edition":"5"},{"key":"468_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"EV Elm","year":"2007","unstructured":"Elm EV, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138.","journal-title":"BMJ"},{"issue":"12","key":"468_CR23","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1046\/j.1360-0443.1998.9312185711.x","volume":"93","author":"J Marsden","year":"1998","unstructured":"Marsden J, Gossop M, Stewart D, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998;93(12):1857\u201368.","journal-title":"Addiction"},{"issue":"1\u20133","key":"468_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.drugalcdep.2008.12.010","volume":"102","author":"SJ Heishman","year":"2009","unstructured":"Heishman SJ, Evans RJ, Singleton EG, Levin KH, Copersino ML, Gorelick DA. Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend. 2009;102(1\u20133):35\u201340. https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.12.010.","journal-title":"Drug Alcohol Depend"},{"key":"468_CR25","unstructured":"Alcohol and Drug Abuse Institute Library [Internet]. Marijuana Craving Questionnaire. Washington: Alcohol & Drug Abuse Institute; [date unknown]. [cited 2020 May 16]. http:\/\/lib.adai.washington.edu\/"},{"key":"468_CR26","unstructured":"NVivo qualitative data analysis software; QSR International Pty Ltd. Version 12, 2018."},{"key":"468_CR27","unstructured":"FaStep Assay. Trimedic Supply Network Ltd.\u00a0https:\/\/www.trimedic-inc.com\/wp-content\/uploads\/2018\/04\/Fastep-Package-Insert.pdf"},{"key":"468_CR28","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"468_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","volume":"35","author":"DR Wesson","year":"2003","unstructured":"Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253\u20139.","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"468_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/09595239996734","volume":"18","author":"D Best","year":"1999","unstructured":"Best D, Gossop M, Greenwood J, Marsden J, Lehmann P, Strang J. Cannabis use in relation to illicit drug use and health problems among opiate misusers in treatment. Drug Alcohol Rev. 1999;18(1):31\u20138.","journal-title":"Drug Alcohol Rev"},{"key":"468_CR31","unstructured":"Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use. Australian Government Publ. Service; 1995."},{"issue":"5","key":"468_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00127-009-0096-3","volume":"45","author":"M Alenius","year":"2010","unstructured":"Alenius M, Hammarlund-Udenaes M, Hartvig P, Lindstr\u00f6m L. Knowledge and insight in relation to functional remission in patients with long-term psychotic disorders. Soc Psychiatry Psychiatr Epidemiol. 2010;45(5):523\u20139.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"7","key":"468_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/0706743718760289","volume":"63","author":"C Rioux","year":"2018","unstructured":"Rioux C, Castellanos-Ryan N, Parent S, Vitaro F, Tremblay RE, S\u00e9guin JR. Age of cannabis use onset and adult drug abuse symptoms: a prospective study of common risk factors and indirect effects. Can J Psychiatry. 2018;63(7):457\u201364. https:\/\/doi.org\/10.1177\/0706743718760289.","journal-title":"Can J Psychiatry"},{"issue":"3","key":"468_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/09595239800187121","volume":"17","author":"MT Lynskey","year":"1998","unstructured":"Lynskey MT, Hall W. Cohort trends in age of initiation to heroin use. Drug Alcohol Rev. 1998;17(3):289\u201397. https:\/\/doi.org\/10.1080\/09595239800187121.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"468_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00406-019-00981-7","volume":"269","author":"C Gorey","year":"2019","unstructured":"Gorey C, Kuhns L, Smaragdi E, Kroon E, Cousijn J. Age-related differences in the impact of cannabis use on the brain and cognition: a systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):37\u201358. https:\/\/doi.org\/10.1007\/s00406-019-00981-7.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"468_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/can.2018.0022","volume":"3","author":"B Wiese","year":"2018","unstructured":"Wiese B, Wilson-Poe AR. Emerging evidence for cannabis\u2019 role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3(1):179\u201389.","journal-title":"Cannabis Cannabinoid Res"},{"key":"468_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7517-6-35","volume":"6","author":"A Reiman","year":"2009","unstructured":"Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduc J. 2009;6:35.","journal-title":"Harm Reduc J"},{"issue":"1","key":"468_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-019-0278-6","volume":"16","author":"P Lucas","year":"2019","unstructured":"Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1):1\u20131.","journal-title":"Harm Reduct J"},{"issue":"1","key":"468_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/can.2016.0010","volume":"1","author":"C Cuttler","year":"2016","unstructured":"Cuttler C, Mischley LK, Sexton M. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. Cannabis Cannabinoid Res. 2016;1(1):166\u201375.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"5","key":"468_CR40","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/adb.12395","volume":"21","author":"R Agabio","year":"2016","unstructured":"Agabio R, Campesi I, Pisanu C, Gessa GL, Franconi F. Sex differences in substance use disorders: focus on side effects. Addict Biol. 2016;21(5):1030\u201342.","journal-title":"Addict Biol"},{"issue":"9","key":"468_CR41","first-page":"796","volume":"49","author":"J Oates","year":"2000","unstructured":"Oates J, Weston WW, Jordan J. The impact of patient-centered care on outcomes. Fam Pract. 2000;49(9):796\u2013804.","journal-title":"Fam Pract"},{"key":"468_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.1996.03530260061033","volume":"275","author":"RM Glass","year":"1996","unstructured":"Glass RM. The patient\u2013physician relationship: JAMA focuses on the center of medicine. JAMA. 1996;275:147\u20138.","journal-title":"JAMA"},{"key":"468_CR43","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1097\/00005650-198903001-00010","volume":"27","author":"SH Kaplan","year":"1989","unstructured":"Kaplan SH, Greenfield S, Ware JE. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care. 1989;27:S110\u201327.","journal-title":"Med Care"},{"issue":"1","key":"468_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s10194-018-0862-2","volume":"19","author":"EP Baron","year":"2018","unstructured":"Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018;19(1):37.","journal-title":"J Headache Pain"},{"key":"468_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00213-004-1825-7","volume":"175","author":"LA Parker","year":"2004","unstructured":"Parker LA, Burton P, Sorge RE, et al. Effect of low doses of \u03949-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology. 2004;175:360\u20136.","journal-title":"Psychopharmacology"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-021-00468-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T13:18:23Z","timestamp":1614086303000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00468-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00468-6","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"5 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained, and the study was conducted in accordance with the ethical guidelines of the Hamilton Integrated Ethics Board (project ID 4556). Participants provided verbal and written informed consent and were able to withdraw from the study at any time.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}